Takaori-Kondo A, Hosono M, Imada K, Yao Z S, Sakahara H, Yamabe H, Konishi J, Okuma M, Uchiyama T
First Department of Internal Medicine, Kyoto University.
Jpn J Cancer Res. 1995 Mar;86(3):322-8. doi: 10.1111/j.1349-7006.1995.tb03058.x.
To clarify the mechanism of in vivo proliferation of adult T cell leukemia (ATL) cells, we examined the organ distribution of ATL-43T cell line cells derived from original leukemic cells in severe combined immunodeficiency (SCID) mice using radiometric techniques. First, we injected 111In-oxine-labeled ATL-43T cells into SCID and CB17 mice. On day 6, significant accumulation of radioactivity was found in the spleen and thymus of SCID mice (33.3 +/- 9.4 and 10.0 +/- 3.6% injected dose/g of tissue [%ID/g], respectively) in comparison with that in CB17 mice (19.1 +/- 2.5 and 3.7 +/- 0.9%ID/g, respectively). Next, we injected radiolabeled anti-Tac monoclonal antibody (MoAb) recognizing human interleukin-2 receptor (IL-2R) alpha chain or isotype-matched control MoAb RPC5 in SCID mice bearing ATL-43T cells 4 weeks after cell inoculation. The amounts of radioactivity found in the spleen and thymus of SCID mice injected with 125I-labeled anti-Tac MoAb (22.5 +/- 6.9 and 22.8 +/- 9.6 %ID/g, respectively) were significantly higher than those in the corresponding organs of SCID mice injected with 125I-labeled RPC5 MoAb (12.0 +/- 5.1 and 7.5 +/- 4.6 %ID/g, respectively). Similar results were obtained with 111In-labeled anti-Tac MoAb. These results were consistent with the histological findings of SCID mice bearing ATL-43T cells, indicating that ATL-43T cells infiltrated preferentially into the lymphoid organs, such as the spleen and thymus, and proliferated there. Thus, the radiometric techniques employed in this study were very useful to evaluate the proliferation sites of ATL-43T cells in SCID mice. Furthermore, this murine model could give us an opportunity to test the feasibility of therapeutic application of radiolabeled anti-Tac MoAb.
为阐明成人T细胞白血病(ATL)细胞在体内增殖的机制,我们使用放射性技术检测了严重联合免疫缺陷(SCID)小鼠中源自原始白血病细胞的ATL-43T细胞系细胞的器官分布。首先,我们将111In-奥克辛标记的ATL-43T细胞注入SCID和CB17小鼠体内。在第6天,与CB17小鼠相比(分别为19.1±2.5和3.7±0.9%注射剂量/克组织 [%ID/g]),在SCID小鼠的脾脏和胸腺中发现了显著的放射性积聚(分别为33.3±9.4和10.0±3.6%ID/g)。接下来,在接种细胞4周后,我们将放射性标记的识别人类白细胞介素-2受体(IL-2R)α链的抗Tac单克隆抗体(MoAb)或同型匹配的对照MoAb RPC5注入携带ATL-43T细胞的SCID小鼠体内。注射125I标记的抗Tac MoAb的SCID小鼠的脾脏和胸腺中发现的放射性量(分别为22.5±6.9和22.8±9.6 %ID/g)显著高于注射125I标记的RPC5 MoAb的SCID小鼠相应器官中的放射性量(分别为12.0±5.1和7.5±4.6 %ID/g)。用111In标记的抗Tac MoAb也获得了类似的结果。这些结果与携带ATL-43T细胞的SCID小鼠的组织学发现一致,表明ATL-43T细胞优先浸润到脾脏和胸腺等淋巴器官中并在那里增殖。因此,本研究中使用的放射性技术对于评估SCID小鼠中ATL-43T细胞的增殖部位非常有用。此外,这种小鼠模型可以为我们提供一个机会来测试放射性标记的抗Tac MoAb治疗应用的可行性。